Skip to main content

Apple executives said in September when the watch was officially announced that the features would be initially available in the United States and available in other countries as they received regulatory approvals.

Brendon Thorne/Bloomberg

Apple Inc. confirms that previously announced software that enables its latest smartwatch to perform electrocardiograms has received Canadian approval but declines to predict when it will be available for download.

The company says in a statement to the Canadian Press that it will bring the heart health features of Apple Watch Series 4 to Canada “as quickly as possible” but a spokeswoman declined to provide an estimated time of arrival.

The statement follows a flurry of social media speculation after reports this week that Health Canada has approved the Apple Watch software for performing ECGs and providing notifications of irregular heart rhythms.

Story continues below advertisement

Apple executives said in September when the watch was officially announced that the features would be initially available in the United States and available in other countries as they received regulatory approvals.

A Health Canada representative said in an e-mail Friday that the government agency’s medical device section has approved two Apple licences but referred questions about Canadian release dates to the manufacturer.

A person with knowledge of Apple’s procedures said on background that the heart features will be enabled in Canada when the company updates the watch’s operating system software but the timing of the update wasn’t known.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies